Alexander M. Lesokhin, MD, is the Interim Service Chief for the Myeloma Service and a member of the Cellular Therapeutics Center. He is also a member of the Ludwig Collaborative laboratory at Memorial Sloan Kettering Cancer Center in New York, New York. He received his MD from the Albert Einstein College of Medicine with distinction in research. Dr Lesokhin’s research focuses on the ability of cancers to evade the immune system and on developing novel treatments to reverse this process. He leads a portfolio of clinical trials testing the clinical and immune effects of antibodies targeting immune agonists, immune checkpoints, bi-specific engagers and adoptive cellular therapies focused in hematologic malignancies. He has additionally developed and validated assays for measuring myeloid-derived suppressor cells (MDSC) as a potential biomarker for efficacy of immune based therapies. His work has resulted in 70 peer-reviewed publications. Dr Lesokhin has received career development awards from the American Cancer Society and the Melanoma Research Alliance and receives additional funding from Cycle for Survival, the Sawiris Foundation, and the Parker Institute for Cancer Immunotherapy.
Episode 3: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics